Health Canada Monograph – Prebiotics

The prebiotic category has reached an important regulatory milestone in Canada. Health Canada has officially published its first dedicated monograph for prebiotics, establishing a structured framework for recognized prebiotic ingredients, claims, dosages and conditions of use exclusively for Natural Health Products.

This publication represents a significant advancement for the microbiome and digestive health market, reinforcing the growing importance of microbiome science in regulatory frameworks worldwide.

As a long-standing member of the Global Prebiotic Association (GPA), Nexira actively contributed to discussions surrounding the development of this monograph. GPA initiated dialogue with Health Canada several years ago and maintained regular engagement throughout the consultation process. GPA’s Regulatory Committee, including Olivier Bove from Nexira, participated in discussions around scientific substantiation, ingredient eligibility and regulatory framework requirements, while Damien Guillemet contributed to scientific exchanges related to the microbiome and prebiotic science.

“This monograph is a major recognition of the maturity reached by the prebiotic category. It provides much-needed regulatory clarity while reinforcing the importance of strong scientific substantiation behind prebiotic claims,” said Olivier Bove, Regulatory Affairs Director at Nexira.

A New Regulatory Recognition for Prebiotics

Until now, regulatory treatment of prebiotics in many regions remained fragmented, with limited harmonization between fiber claims and microbiome-related health benefits.

The new Health Canada monograph changes this by formally recognizing prebiotics under a dedicated regulatory framework for Natural Health Products (NHPs).

Importantly, the monograph clearly distinguishes:

• dietary fibers,
• and clinically supported prebiotics.

Health Canada explicitly states that not all fibers are prebiotics, and not all prebiotics are fibers.

This distinction represents a major validation for ingredients supported by robust microbiome science.

Acacia Gum Officially Recognized as a Prebiotic

Among the ingredients included in the monograph, acacia gum is now officially recognized as a prebiotic ingredient alongside:

• inulin,
• FOS,
• GOS,
• XOS,
• and selected HMOs.

This inclusion reinforces the growing body of evidence supporting acacia’s microbiome benefits and digestive health properties.

The monograph also specifies dosage ranges and acceptable claims associated with listed ingredients. For acacia gum, prebiotic efficacy is recognized within defined use conditions.

Recognized claims include:

• “Prebiotic”
• “Helps stimulate the growth of healthy bacteria in the intestine/gut”
• “Helps support and maintain a healthy digestive system.”

“For years, science related to gut microbiota has demonstrated that acacia fiber delivers benefits beyond simple fiber enrichment. Seeing acacia officially recognized as a prebiotic ingredient validates decades of scientific research on digestive tolerance, microbiota modulation and benefits for host,” added Damien Guillemet, Scientific Development Director at Nexira.

Stronger Credibility for Microbiome Science

The publication of this monograph confirms the increasing role of microbiome science in regulatory decision-making.

Rather than focusing solely on fiber enrichment or bulking functionality, the framework recognizes clinically supported benefits related to:

• beneficial gut bacteria,
• digestive health,
• microbiota modulation,
• and prebiotic effects.

For science-backed ingredients such as acacia gum, this represents an important evolution toward more differentiated and evidence-based positioning.

“The industry is moving from generic fiber communication toward prebiotic activities with microbiome modulation and ultimately final benefits supported by clinical evidence. This monograph reflects that evolution and need to clarify the distinctions,” said Damien Guillemet.

Faster Market Access for Brands

Another major implication of the monograph is regulatory simplification for Natural Health Products.

For ingredients included within the framework, brands developing Natural Health Products in Canada may benefit from:

• simplified regulatory pathways,
• reduced documentation burden,
• faster product approval,
• and clearer claim substantiation.

This can significantly accelerate time-to-market for prebiotic supplements and digestive health solutions.

“For brands, regulatory predictability is critical. This framework helps reduce uncertainty and facilitates innovation for clinically supported prebiotic ingredients,” commented Olivier Bove.

A Competitive Advantage for Science-Backed Prebiotics

The monograph also creates stronger differentiation between established prebiotic ingredients and fibers that are not currently included in the framework.

This creates a clearer regulatory positioning for recognized prebiotics such as acacia gum and reinforces the value of strong clinical and microbiome science.

Reinforcing Nexira’s Leadership in Gentle Prebiotic Fibers

As a global leader in acacia and a pioneer in microbiome-focused fiber innovation, Nexira welcomes this important regulatory advancement.

For decades, Nexira has invested in scientific research demonstrating the digestive tolerance, microbiome modulation and prebiotic properties of acacia fiber. The inclusion of acacia gum in the Health Canada monograph further validates this long-standing scientific expertise.

At a time when consumers increasingly seek clinically supported digestive health solutions, gentle prebiotic fibers backed by science are becoming more relevant than ever.

“This milestone reinforces Nexira’s long-term vision on acacia fiber: combining natural origin, digestive tolerance and strong science on microbiota improvements and correlated health benefits to support next-generation prebiotic solutions,” concluded Damien Guillemet.

This communication is not intended to the final consumer. It provides scientific information for professionals only. Communication to final consumer has to be checked according to local regulation in force, since the conditions of use are beyond our control. This statement has not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease.